The AABB website is currently experiencing technical issues related to login and SSO. Thank you for your patience as we work to get this resolved. If you need immediate assistance, please contact us.
Association Bulletins provide a mechanism for publication of documents that have been approved by the Board of Directors for distribution to individual and institutional members, such as:
#25-01 - Association Bulletin Listings - 05/23/25
Listing of AABB Association Bulletins
Current as of April 19, 2024
Date | Association Bulletin | Revision Highlighted (when applicable) | Title |
08/02/24 | #24-04 | N/A | Emergent Standards for the 11th edition of Standards for Cellular Therapy Services |
08/02/24 | #24-03 | N/A | Emergent Standards for the 34th edition of Standards for Blood Banks and Transfusion Services |
07/15/24 | #24-02 | N/A | Use of Rh Immune Globulin and Considerations in the Setting of Supply Shortages and Limited Availability |
03/03/23 | #23-02 | N/A | Pretransfusion Hemoglobin Thresholds for Chronic Nonemergent Red Blood Cell Transfusions in β Thalassemia |
06/02/21 | #21-02 | N/A | Impact of the FDA Guidance "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion" |
06/26/19 | #19-02 | #19-02 Revised May 2025 | Recommendations on the Use of Group O Red Blood Cells |
03/16/17 | #17-02 | #17-02 Revised July 2022 | Updated Strategies to Limit or Prevent Iron Deficiency in Blood Donors |
01/15/16 | #16-02 | #16-02 Revised April 2024 | Mitigating the Anti-CD38 Interference with Serologic Testing |
12/28/15 | #15-02 | #15-02 Revised February 2023 | Transfusion-Associated Circulatory Overload (TACO) |
07/18/14 | #14-05 | N/A | Babesiosis |
01/29/14 | #14-02 | N/A | TRALI Risk Mitigation for Plasma and Whole Blood for Allogeneic Transfusion |
07/25/13 | #13-03 | N/A | Updated Criteria for Donor Deferral and Blood Component Retrieval in Known or Suspected Common Source Outbreaks of Hepatitis A Virus Infection |
09/21/12 | #12-02 | N/A | TRALI Risk Mitigation Update |
08/28/08 | #08-04 | #08-04 Revised July 2022 | Strategies to Reduce Adverse Reactions and Injuries in Younger Donors |
08/30/06 | #06-05 | #06-05 Revised May 2025 | Monitoring and Preventing the Occurrence of Deviations and Near-Miss Events in Pretransfusion Testing: Mislabeling/Wrong Blood in Tube |
01/24/05 | #05-02 | #05-02 Revised July 2022 | Guidance on Management of Blood and Platelet Donors with Positive or Abnormal Results on Bacterial Contamination Tests (Supplements #04-07) |
10/14/04 | #04-07 | #04-07 Revised July 2022 | Actions Following an Initial Positive Test for Possible Bacterial Contamination of a Platelet Unit |
AABB is now the Association for the Advancement of Blood & Biotherapies. Learn more about our new name and brand – and watch as we evolve throughout 2022.
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide.
©2022 All Rights Reserved. AABB - Association for the Advancement of Blood & Biotherapies
Web Design and Development by Matrix Group International, Inc.